Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
Wyatt B Messenger, Robert M Beardsle, Christina J FlaxelCasey Eye Institute, Oregon Health and Science University, Portland, OR, USAAbstract: Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser photocoagulation was the standard of care for...
Saved in:
Main Authors: | Messenger WB (Author), Beardsley RM (Author), Flaxel CJ (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2013-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
by: Stéphanie Baillif, et al.
Published: (2022) -
Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema
by: Lucy Joanne Kessler, et al.
Published: (2022) -
Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study
by: Thibaud Mathis, et al.
Published: (2022) -
Efficacy and Safety of Fluocinolone Acetonide Implant in Diabetic Macular Edema: Practical Guidelines from Reference Center
by: Lucas Sejournet, et al.
Published: (2024) -
Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review
by: Laurent Kodjikian, et al.
Published: (2021)